XTL Biopharmaceuticals Ltd.
XTLBAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| H.C. Wainwright | maintain | Buy | May 8, 2015 |
| HC Wainwright & Co. | maintain | Buy | May 8, 2015 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Dec 31, 2024 | $-0.00 | — | $1.6M | — |
| Sep 30, 2024 | $-0.00 | — | $613.4K | — |
| Jun 30, 2024 | $-0.00 | — | — | — |
| Apr 30, 2024 | $0.00 | — | — | — |
| Mar 5, 2024 | $-0.00 | — | — | — |
| Jun 30, 2023 | $-0.00 | — | — | — |
| Mar 31, 2023 | $-0.01 | — | — | — |
| Mar 22, 2023 | $-0.01 | — | — | — |
News
Burning Rock Biotech (NASDAQ: BNR - Get Free Report) and XTL Biopharmaceuticals (NASDAQ: XTLB - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation. Volatility and Risk Burning Rock Biotech
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB - Get Free Report) was the recipient of a significant drop in short interest in the month of September. As of September 15th, there was short interest totaling 7,172 shares, a drop of 36.1% from the August 31st total of 11,229 shares. Currently, 0.4% of the shares of the company are
DBV Technologies (NASDAQ: DBVT - Get Free Report) and XTL Biopharmaceuticals (NASDAQ: XTLB - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation. Profitability This table compares DBV Technologies and